Noticias

Noticias

  • Título: InspireMD Announces Full Market Launch of CGuardTM Distributed by Penumbra at CIRSE Annual Congress
  • Fecha: 28-09-2015

  • BOSTON, MA – September 28, 2015 – InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, announced today the full market launch of the CGuardTM Embolic Prevention System for the treatment of carotid artery disease by its strategic distribution partner, Penumbra, Inc. (NYSE: PEN), at the CIRSE Annual Congress in Lisbon, Portugal. Penumbra, a global interventional therapies company that designs, develops, manufactures and markets innovative medical devices to the neurovascular and peripheral vascular communities, leverages its direct European commercialization team to launch CGuardTM Distributed by Penumbra. The 2015 Congress marks the 30th year of CIRSE, Cardiovascular and Interventional Radiological Society of Europe, which aims to be a leader in interventional radiology (IR) education, drawing over 6,500 attendees from the medical community across 90 countries.

    At CIRSE 2015, Penumbra hosted a well-attended physician symposium titled, “CGuardTM – MicroNet Covered Embolic Prevention Stent System: A Game-Changer in CAS” led by Prof. Piotr Musialek on Sunday, September 27th. Dr. Musialek is principle investigator in the all comer PARADIGM study that continues to document both the short term and long term benefits of using the MicroNet covered CGuard technology in patients with carotid artery disease. In-booth demonstrations, teaching materials, and clinical case studies were also featured for conference attendees.

    Alan Milinazzo, CEO of InspireMD, commented, “We are excited that our partner, Penumbra, has begun its full commercial launch of CGuard at CIRSE, a respected venue for learning about new technologies in the IR, vascular, and neurovascular community. Early feedback from physician attendees has been positive, with follow on meetings scheduled, in addition to discussions on additional possible uses of the MicroNetTM technology in the neurovascular space.” Milinazzo continued, “The Penumbra commercial team is strong and growing, with a well-established footprint across all specialists that manage carotid artery disease. We are confident of successful commercial progress in the coming months and look forward to supporting Penumbra as we introduce this breakthrough technology to our customers.”

    In addition, Jim Pray, President, International of Penumbra, stated, “The Penumbra team believes that the CGuard technology will give our customers a new, proven alternative to traditional treatment options for patients with carotid artery disease. We have been trained on the CGuard technology and are officially launching it here at the CIRSE meeting this week. We look forward to working with our customers to provide them with this exciting new carotid embolic prevention system.”

    About PARADIGM

    PARADIGM is an investigator-initiated Prospective evaluation of All-comer peRcutaneous cArotiD revascularization In symptomatic and increased-risk asymptomatic carotid artery stenosis, using CGuard™ Mesh-covered embolic prevention stent system. At EuroPCR 2015, Dr. Musialek summarized his clinical presentation of 71 CGuard procedures in unselected all-comer patients in the PARADIGM evaluation as: 1) stent system success and procedure success rate of 100%; 2) periprocedural complications of 0%, and remained at 0% at 30 days; and 3) no MACNE occurred periprocedurally or at 30 days, by operator-independent neurologist and non-invasive cardiologist evaluation.



  • Fuente: endovascular.es